Get the Stockscreener App
2.61
5.24%
0.13
After Hours:
2.60
-0.010
-0.38%
Genelux Corp stock is traded at $2.61, with a volume of 95,550.
It is up +5.24% in the last 24 hours and down -0.76% over the past month.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
See More
Previous Close:
$2.48
Open:
$2.45
24h Volume:
95,550
Relative Volume:
0.53
Market Cap:
$98.50M
Revenue:
-
Net Income/Loss:
$-27.66M
P/E Ratio:
-2.7474
EPS:
-0.95
Net Cash Flow:
$-24.36M
1W Performance:
-6.12%
1M Performance:
-0.76%
6M Performance:
+5.24%
1Y Performance:
-28.49%
1-Day Range:
$2.41
$2.61
1-Week Range:
$2.30
$2.83
52-Week Range:
$1.60
$5.885
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.61 | 104.90M | 0 | -27.66M | -24.36M | -0.95 |
|
ONC
Beigene Ltd Adr
|
233.37 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.54 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.58 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
Genelux Corp Stock (GNLX) Latest News
Top Executives at Genelux Corp. Unload Thousands of Shares! - TipRanks
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView
Genelux Q3 EPS Raised by Brookline Capital Management - Defense World
HC Wainwright Issues Optimistic Outlook for Genelux Earnings - Defense World
Genelux Corp.’s Promising Prospects: Buy Rating Backed by Strong Phase 3 Trial and Financial Position - TipRanks
Genelux (GNLX) Price Target Lowered by Benchmark Analyst | GNLX Stock News - GuruFocus
Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating - TipRanks
H.C. Wainwright lifts Genelux stock target to $31, maintains buy By Investing.com - Investing.com Nigeria
Genelux reports Q1 EPS (21c), consensus (24c) - TipRanks
Genelux (GNLX) Shows Strong Progress in Cancer Treatment Trials | GNLX Stock News - GuruFocus
Genelux Reports 71% Disease Control Rate in Lung Cancer Trial, Q1 2025 Earnings | GNLX Stock News - Stock Titan
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates - Yahoo Finance
Geode Capital Management LLC Has $716,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux CEO Discusses Next-Gen Immuno-Oncology Pipeline and Key Milestones at Citizens Conference - Stock Titan
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference - Yahoo Finance
LPL Financial LLC Has $222,000 Stock Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Raymond James Financial Inc. Takes $41,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Benchmark maintains $25 target on Genelux stock, optimistic on trials - Investing.com
Benchmark maintains $25 target on Genelux stock, optimistic on trials By Investing.com - Investing.com India
HC Wainwright Has Bearish Estimate for Genelux Q1 Earnings - The AM Reporter
Guggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX) - The Globe and Mail
Analysts Offer Predictions for Genelux Q1 Earnings - Defense World
What is HC Wainwright’s Forecast for Genelux Q1 Earnings? - Defense World
Genelux (NASDAQ:GNLX) Given Buy Rating at HC Wainwright - Defense World
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements - TipRanks
H.C. Wainwright maintains Buy on Genelux shares, target at $30 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Genelux shares, target at $30 - Investing.com
Genelux Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Brokers Set Expectations for Genelux FY2024 Earnings - Defense World
Research Analysts Set Expectations for Genelux Q1 Earnings - The AM Reporter
Genelux reports FY24 EPS (95c), consensus (88c) - TipRanks
FDA Green Light: Genelux's Cancer Drug Olvi-Vec Advances as 2024 Data Shows 71% Disease Control - Stock Titan
GENELUX Corp SEC 10-K Report - TradingView
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround - Yahoo Finance
Genelux (GNLX) Projected to Post Quarterly Earnings on Friday - Defense World
Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp. - TipRanks
What is HC Wainwright’s Estimate for Genelux Q1 Earnings? - Defense World
Benchmark maintains $25 target on Genelux following trial data - Investing.com
Genelux’s (GNLX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Genelux stock holds Buy rating, $30 target from H.C. Wainwright - Investing.com India
Genelux prices 3M shares at $3.50 in underwritten public offering - TipRanks
Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec - TipRanks
Genelux announces alignment with FDA of approval pathway for Olvi-Vec - TipRanks
Genelux Announces FDA Guidance on Olvi-Vec Phase 3 Trial - MarketScreener
Genelux Prices 3 Mln Stock Offering At $3.50/shr, Stock Fell - Nasdaq
Genelux's Olvi-Vec Shows Anti-Tumor Effect in Phase 1b/2 Lung Cancer Study - Marketscreener.com
Genelux Prices $10.5 Million Stock Offering - MarketScreener
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock - GlobeNewswire
$10.5M Capital Raise: How Genelux Plans to Accelerate Cancer Drug Pipeline - Stock Titan
Breakthrough: Cancer Drug Achieves 79% Tumor Reduction in Advanced Lung Cancer Study - Stock Titan
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):